This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biogen (BIIB) Q3 Earnings Coming Up: What's in the Cards?
by Zacks Equity Research
On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance.
Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.
Alnylam to Pursue Full Approval & Rolling NDA for Givosiran
by Zacks Equity Research
Alnylam (ALNY) plans to pursue a full approval of givosiran and submit rolling new drug application (NDA) for the same.
Roche Announces Positive Data on Breast Cancer Drug Kadcyla
by Zacks Equity Research
Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.
Corium's (CORI) Shares Surge on Merger Agreement With Gurnet
by Zacks Equity Research
Corium International (CORI) announces merger agreement with Gurnet Point Capital. The deal values Corium at $12.50 per share in cash and will take the company private.
Immune Design to Halt Cancer Vaccine Program, Shares Plunge
by Zacks Equity Research
Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.
Bristol-Myers Reports Disappointing Data From SCLC Study
by Zacks Equity Research
Bristol-Myers??? (BMY) late-stage study on blockbuster immuno-oncology drug, Opdivo for the treatment of SCLC fails.
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
by Zacks Equity Research
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Teva Gets FDA Committee Nod for Rituxan Biosimilar Filing
by Zacks Equity Research
Teva (TEVA) and partner Celltrion gets unanimous vote from an FDA advisory committee recommending approval of CT-P10, their proposed biosimilar to Roche's Rituxan.
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus
by Zacks Equity Research
Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatment.
Affimed Down After Clinical Hold on Two Early-Stage Studies
by Zacks Equity Research
Affimed (AFMD) puts two phase I studies evaluating its CD19/CD3-targeting T cell engager, AFM11, on clinical hold due to one death and two life-threatening events.
AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis
by Zacks Equity Research
AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.
J&J Inks Deal With Arrowhead for Promising Liver Candidate
by Zacks Equity Research
Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.
Roche's Hemlibra Receives FDA Approval for Label Expansion
by Zacks Equity Research
Roche (RHHBY) obtains the FDA approval for the label expansion of Hemlibra for the treatment of adults and children suffering haemophilia A without factor VIII inhibitors.
Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data
by Zacks Equity Research
Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.
Lilly's Novel Diabetes Candidate Shows Promise in Phase II
by Zacks Equity Research
Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.
Roche Holding, YY, eBay and PayPal highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Roche Holding, YY, eBay and PayPal highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Roche (RHHBY)
by Kevin Cook
With 3 of the top-ten cancer drugs globally, this Swiss giant is looking for the next I/O breakthroughs
Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam
by Zacks Equity Research
Roche (RHHBY) reports encouraging data from two pivotal studies -- FIREFISH and SUNFISH -- on risdiplam for the treatment of Spinal Muscular Atrophy.
BioLineRx Stock Up on Stake Increase in Lead Cancer Program
by Zacks Equity Research
BioLineRx (BLRX) signs an agreement with Biokine Therapeutics to raise its economic interest in its lead oncology platform, BL-8040, by 20%.
Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies
by Zacks Equity Research
Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-inferiorly to Humalog.
Here's Why J&J (JNJ) is a Good Bet in a Troubled Market
by Zacks Equity Research
A diversified portfolio, robust pipeline, strong growth of new drugs and a consistent dividend payout make Johnson & Johnson (JNJ) a good bet amid market turmoil as well as over the long term.
Novartis, Boston Pharma Ink Deal for 3 Anti-Infective Drugs
by Zacks Equity Research
Novartis inks licensing deal with Boston Pharma for the development of three novel anti-infective drug candidates.
Dr. Reddy's Sells Antibiotic Production Hub to UAE Drugmaker
by Zacks Equity Research
Dr. Reddy's (RDY) divests its Bristol, TN-based antibiotic manufacturing site and related assets to an Abu Dhabi-based company.
Roche Gets FDA Approval for New Formulation of Asthma Drug
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair.